Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation

Yuanjie Niu, Shuyuan Yeh, Hiroshi Miyamoto, Gonghui Li, Saleh Altuwaijri, Jianqun Yuan, Ruifa Han, Tengxiang Ma, Hann Chorng Kuo, Chawnshang Chang

Research output: Contribution to journalArticle

Abstract

Despite being well recognized as the best biomarker for prostate cancer, pathophysiologic roles of prostate-specific antigen (PSA) remain unclear. We report here that tissue PSA may be involved in the hormone-refractory prostate cancer progression. Histologic analyses show that the increased tissue PSA levels are correlated with lower cell apoptosis index and higher cell proliferation rate in hormone-refractory tumor specimens. By stably transfecting PSA cDNA into various prostate cancer cell lines, we found that PSA could promote the growth of androgen receptor (AR)-positive CWR22rv1 and high-passage LNCaP (hormone-refractory prostate cancer cells) but not that of AR-negative PC-3 and DU145 cells. Surprisingly, the protease activity of PSA is not crucial for PSA to stimulate growth and promote AR transactivation. We further showed that increased PSA could enhance ARA70-induced AR transactivation via modulating the p53 pathway that results in the decreased apoptosis and increased cell proliferation in prostate cancer cells. Knockdown of PSA in LNCaP and CWR22rv1 cells causes cell apoptosis and cell growth arrest at the G1 phase. In vitro colony formation assay and in vivo xenografted tumor results showed the suppression of prostate cancer growth via targeting PSA expression. Collectively, our findings suggest that, in addition to being a biomarker, PSA may also become a new potential therapeutic target for prostate cancer. PSA small interfering RNA or smaller molecules that can degrade PSA protein may be developed as alternative approaches to treat the prostate cancer.

Original languageEnglish (US)
Pages (from-to)7110-7119
Number of pages10
JournalCancer Research
Volume68
Issue number17
DOIs
StatePublished - Sep 1 2008
Externally publishedYes

Fingerprint

Androgen Receptors
Prostate-Specific Antigen
Transcriptional Activation
Prostate
Prostatic Neoplasms
Neoplasms
Hormones
Apoptosis
Growth
Biomarkers
Cell Proliferation
G1 Phase
Small Interfering RNA
Peptide Hydrolases
Complementary DNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. / Niu, Yuanjie; Yeh, Shuyuan; Miyamoto, Hiroshi; Li, Gonghui; Altuwaijri, Saleh; Yuan, Jianqun; Han, Ruifa; Ma, Tengxiang; Kuo, Hann Chorng; Chang, Chawnshang.

In: Cancer Research, Vol. 68, No. 17, 01.09.2008, p. 7110-7119.

Research output: Contribution to journalArticle

Niu, Y, Yeh, S, Miyamoto, H, Li, G, Altuwaijri, S, Yuan, J, Han, R, Ma, T, Kuo, HC & Chang, C 2008, 'Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation', Cancer Research, vol. 68, no. 17, pp. 7110-7119. https://doi.org/10.1158/0008-5472.CAN-07-6507
Niu, Yuanjie ; Yeh, Shuyuan ; Miyamoto, Hiroshi ; Li, Gonghui ; Altuwaijri, Saleh ; Yuan, Jianqun ; Han, Ruifa ; Ma, Tengxiang ; Kuo, Hann Chorng ; Chang, Chawnshang. / Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. In: Cancer Research. 2008 ; Vol. 68, No. 17. pp. 7110-7119.
@article{468bd9f1678b4253b61c6e6b1a835f32,
title = "Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation",
abstract = "Despite being well recognized as the best biomarker for prostate cancer, pathophysiologic roles of prostate-specific antigen (PSA) remain unclear. We report here that tissue PSA may be involved in the hormone-refractory prostate cancer progression. Histologic analyses show that the increased tissue PSA levels are correlated with lower cell apoptosis index and higher cell proliferation rate in hormone-refractory tumor specimens. By stably transfecting PSA cDNA into various prostate cancer cell lines, we found that PSA could promote the growth of androgen receptor (AR)-positive CWR22rv1 and high-passage LNCaP (hormone-refractory prostate cancer cells) but not that of AR-negative PC-3 and DU145 cells. Surprisingly, the protease activity of PSA is not crucial for PSA to stimulate growth and promote AR transactivation. We further showed that increased PSA could enhance ARA70-induced AR transactivation via modulating the p53 pathway that results in the decreased apoptosis and increased cell proliferation in prostate cancer cells. Knockdown of PSA in LNCaP and CWR22rv1 cells causes cell apoptosis and cell growth arrest at the G1 phase. In vitro colony formation assay and in vivo xenografted tumor results showed the suppression of prostate cancer growth via targeting PSA expression. Collectively, our findings suggest that, in addition to being a biomarker, PSA may also become a new potential therapeutic target for prostate cancer. PSA small interfering RNA or smaller molecules that can degrade PSA protein may be developed as alternative approaches to treat the prostate cancer.",
author = "Yuanjie Niu and Shuyuan Yeh and Hiroshi Miyamoto and Gonghui Li and Saleh Altuwaijri and Jianqun Yuan and Ruifa Han and Tengxiang Ma and Kuo, {Hann Chorng} and Chawnshang Chang",
year = "2008",
month = "9",
day = "1",
doi = "10.1158/0008-5472.CAN-07-6507",
language = "English (US)",
volume = "68",
pages = "7110--7119",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "17",

}

TY - JOUR

T1 - Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation

AU - Niu, Yuanjie

AU - Yeh, Shuyuan

AU - Miyamoto, Hiroshi

AU - Li, Gonghui

AU - Altuwaijri, Saleh

AU - Yuan, Jianqun

AU - Han, Ruifa

AU - Ma, Tengxiang

AU - Kuo, Hann Chorng

AU - Chang, Chawnshang

PY - 2008/9/1

Y1 - 2008/9/1

N2 - Despite being well recognized as the best biomarker for prostate cancer, pathophysiologic roles of prostate-specific antigen (PSA) remain unclear. We report here that tissue PSA may be involved in the hormone-refractory prostate cancer progression. Histologic analyses show that the increased tissue PSA levels are correlated with lower cell apoptosis index and higher cell proliferation rate in hormone-refractory tumor specimens. By stably transfecting PSA cDNA into various prostate cancer cell lines, we found that PSA could promote the growth of androgen receptor (AR)-positive CWR22rv1 and high-passage LNCaP (hormone-refractory prostate cancer cells) but not that of AR-negative PC-3 and DU145 cells. Surprisingly, the protease activity of PSA is not crucial for PSA to stimulate growth and promote AR transactivation. We further showed that increased PSA could enhance ARA70-induced AR transactivation via modulating the p53 pathway that results in the decreased apoptosis and increased cell proliferation in prostate cancer cells. Knockdown of PSA in LNCaP and CWR22rv1 cells causes cell apoptosis and cell growth arrest at the G1 phase. In vitro colony formation assay and in vivo xenografted tumor results showed the suppression of prostate cancer growth via targeting PSA expression. Collectively, our findings suggest that, in addition to being a biomarker, PSA may also become a new potential therapeutic target for prostate cancer. PSA small interfering RNA or smaller molecules that can degrade PSA protein may be developed as alternative approaches to treat the prostate cancer.

AB - Despite being well recognized as the best biomarker for prostate cancer, pathophysiologic roles of prostate-specific antigen (PSA) remain unclear. We report here that tissue PSA may be involved in the hormone-refractory prostate cancer progression. Histologic analyses show that the increased tissue PSA levels are correlated with lower cell apoptosis index and higher cell proliferation rate in hormone-refractory tumor specimens. By stably transfecting PSA cDNA into various prostate cancer cell lines, we found that PSA could promote the growth of androgen receptor (AR)-positive CWR22rv1 and high-passage LNCaP (hormone-refractory prostate cancer cells) but not that of AR-negative PC-3 and DU145 cells. Surprisingly, the protease activity of PSA is not crucial for PSA to stimulate growth and promote AR transactivation. We further showed that increased PSA could enhance ARA70-induced AR transactivation via modulating the p53 pathway that results in the decreased apoptosis and increased cell proliferation in prostate cancer cells. Knockdown of PSA in LNCaP and CWR22rv1 cells causes cell apoptosis and cell growth arrest at the G1 phase. In vitro colony formation assay and in vivo xenografted tumor results showed the suppression of prostate cancer growth via targeting PSA expression. Collectively, our findings suggest that, in addition to being a biomarker, PSA may also become a new potential therapeutic target for prostate cancer. PSA small interfering RNA or smaller molecules that can degrade PSA protein may be developed as alternative approaches to treat the prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=52049114665&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52049114665&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-07-6507

DO - 10.1158/0008-5472.CAN-07-6507

M3 - Article

C2 - 18757426

AN - SCOPUS:52049114665

VL - 68

SP - 7110

EP - 7119

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 17

ER -